| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/16/2011 | US20110142872 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 06/16/2011 | US20110142871 Compounds and methods for diagnosis and immunotherapy of tuberculosis |
| 06/16/2011 | US20110142865 Tumor-associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules |
| 06/16/2011 | US20110142864 Tumor-associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules |
| 06/16/2011 | US20110142856 Compound containing basic group and use thereof |
| 06/16/2011 | US20110142855 Compounds Having CRTH2 Antagonist Activity |
| 06/16/2011 | US20110142854 Compositions and methods for inhibition of retroviruses |
| 06/16/2011 | US20110142848 Anti-beta-2-microglobulin agents and the use thereof |
| 06/16/2011 | US20110142846 Method for diagnosing and treating emphysema |
| 06/16/2011 | US20110142842 Polypeptides |
| 06/16/2011 | US20110142836 B-cell depleting agents for the treatment of chronic fatigue syndrome |
| 06/16/2011 | US20110142829 Anti-tumour compositions and methods |
| 06/16/2011 | US20110142828 Treatment prediction involving hmgcr |
| 06/16/2011 | US20110142826 Azaindolizines and methods of use |
| 06/16/2011 | US20110142820 Novel Targets for Regulation of Angiogenesis |
| 06/16/2011 | US20110142818 Combination enzyme replacement and small molecule therapy for treatment of lysosomal storage diseases |
| 06/16/2011 | US20110142816 Thermostabilization of proteins |
| 06/16/2011 | US20110142815 Compounds, composition, methods, targets for cancer therapy |
| 06/16/2011 | US20110142799 Modulation of neurodegenerative disease by modulating xbp-1 activity |
| 06/16/2011 | US20110142798 Hepatitis c virus inhibitors |
| 06/16/2011 | US20110142797 Method For Prophylaxis or Treatment of Feline Infectious Peritonitis |
| 06/16/2011 | US20110142796 Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors |
| 06/16/2011 | US20110142795 Methods of treating cognitive impairment |
| 06/16/2011 | US20110142794 Methods and Compositions to Determine the Chemosensitizing Dose of Suramin Used in Combination Therapy |
| 06/16/2011 | US20110142790 Polyol Based - Bioceramic Composites |
| 06/16/2011 | US20110142789 Compositions and Methods for the Diagnosis and Treatment of Amyotrophic Lateral Sclerosis |
| 06/16/2011 | US20110142777 Use of indole compounds as a cosmetic |
| 06/16/2011 | US20110142776 Divinyl ether derivatives capable of releasing active aldehydes and ketones and methods of use for perfuming surfaces |
| 06/16/2011 | US20110142771 Photostabilization of Retinoids with Alkoxycrylene Compounds |
| 06/16/2011 | US20110142769 Low toxicity topical active agent delivery system |
| 06/16/2011 | US20110142767 RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS |
| 06/16/2011 | US20110142765 Novel phloroglucinol derivatives having selectin ligand activity |
| 06/16/2011 | US20110142764 Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases |
| 06/16/2011 | US20110142757 Novel compounds and their uses in diagnosis |
| 06/16/2011 | US20110139654 Oxadiazole derivatives for the treatment of diabetes |
| 06/16/2011 | US20110139152 Antibiotic microparticles for inhalation |
| 06/16/2011 | US20110138888 Treatment of obesity |
| 06/16/2011 | DE102009058321A1 Schmelztablette, enthaltend Dapoxetin Melting tablet containing dapoxetine |
| 06/16/2011 | CA2821034A1 Method of treating pancreatic cancer |
| 06/16/2011 | CA2784928A1 Pharmaceutical composition for treating cutaneous burns |
| 06/16/2011 | CA2784001A1 Nanoparticle carrier systems based on human serum albumin for photodynamic therapy |
| 06/16/2011 | CA2783962A1 Method for late introduction of the (8r)-hydroxyl group in carbapenem .beta.-lactam antibiotic synthesis |
| 06/16/2011 | CA2783958A1 Oxazine derivative |
| 06/16/2011 | CA2783934A1 Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators |
| 06/16/2011 | CA2783929A1 5-amino-4-hydroxypentoyl amides |
| 06/16/2011 | CA2783859A1 N6-substituted adenosine derivatives and n6-substituted adenine derivatives and uses thereof |
| 06/16/2011 | CA2783851A1 Novel oxadiazole compounds |
| 06/16/2011 | CA2783707A1 Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof |
| 06/16/2011 | CA2783701A1 Selective beta-glucuronidase inhibitors as a treatment for side effects of camptothecin antineoplastic agents |
| 06/16/2011 | CA2783699A1 Compounds and methods of treating ocular disorders |
| 06/16/2011 | CA2783684A1 Inhibitors of diacylglycerol acyltransferase |
| 06/16/2011 | CA2783540A1 Pyridinone hydroxycyclopentyl carboxamides: hiv integrase inhibitors with therapeutic applications |
| 06/16/2011 | CA2783537A1 Benzamide compound |
| 06/16/2011 | CA2783535A1 Stable formulations for lyophilizing therapeutic particles |
| 06/16/2011 | CA2783466A1 Amyloid binding agents |
| 06/16/2011 | CA2783405A1 N-substituted deoxynojirimycin compounds for use in inhibiting osteoclastogenesis and/or osteoclast activation |
| 06/16/2011 | CA2783314A1 4-oxo-1h-quinoline-3-carboxamides as modulators of atp-binding cassette transporters |
| 06/16/2011 | CA2783236A1 Improved methods and compositions for vein harvest and autografting |
| 06/16/2011 | CA2782946A1 4- (azacycloalkyl) -benzene-1, 3 -diol derivatives as tyrosinase inhibitors and their synthesis and use thereof |
| 06/16/2011 | CA2782779A1 Mucoadhesive buccal tablets for the treatment of orofacial herpes |
| 06/16/2011 | CA2782725A1 Process and product |
| 06/16/2011 | CA2782624A1 Therapeutic use of protein-polymer conjugates |
| 06/16/2011 | CA2782514A1 Methods of improving cognitive functions |
| 06/16/2011 | CA2782409A1 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands |
| 06/16/2011 | CA2782384A1 Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds |
| 06/16/2011 | CA2782294A1 Cysteine protease inhibitors |
| 06/16/2011 | CA2782292A1 Cysteine protease inhibitors |
| 06/16/2011 | CA2782248A1 Bis-acylated hydroxylamine derivatives |
| 06/16/2011 | CA2782110A1 N-acyloxysulfonamide and n-hydroxy-n-acylsulfonamide derivatives |
| 06/16/2011 | CA2782015A1 Compositions and methods for the treatment of macular degeneration |
| 06/16/2011 | CA2781896A1 Modulation of hsp47 expression |
| 06/16/2011 | CA2781888A1 Agents and methods for treating ischemic and other diseases |
| 06/16/2011 | CA2781839A1 Spiro indole - cyclopropane indolinones useful as ampk modulators |
| 06/16/2011 | CA2781821A1 Processes for the preparation of deferasirox, and deferasirox polymorphs |
| 06/16/2011 | CA2781717A1 Dock-and-lock (dnl) complexes for delivery of interference rna |
| 06/16/2011 | CA2781685A1 Imidazolidinedione derivatives |
| 06/16/2011 | CA2781431A1 Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof |
| 06/16/2011 | CA2781233A1 Novel therapeutic methods for treating inflammation and immune system disorders |
| 06/16/2011 | CA2781218A1 Heterocyclic sulfonamide derivatives |
| 06/16/2011 | CA2780905A1 Azocyclic inhibitors of fatty acid amide hydrolase |
| 06/16/2011 | CA2780859A1 Fty720 halogenated derivatives |
| 06/16/2011 | CA2780693A1 Amino oxazine derivatives |
| 06/16/2011 | CA2777907A1 Fluoro-substituted 2-aryl-3,5-dicyano-4-indazolyl-6-methyl-1,4-dihydropyridines and uses thereof |
| 06/16/2011 | CA2776727A1 2-amino-5, 5-difluoro-5, 6-dihydro-4h-oxazines as bace 1 and/or bace 2 inhibitors |
| 06/16/2011 | CA2690450A1 Mesalamine suppository |
| 06/16/2011 | CA2688661A1 Polyphenol-containing products |
| 06/15/2011 | EP2333094A1 Production of polyunsaturated fatty acids using novel cell treatment method |
| 06/15/2011 | EP2333093A1 Preparation of microbial oil containing polyunsaturated fatty acids |
| 06/15/2011 | EP2333064A1 Nucleotide and protein sequences of Nogo genes and methods based thereon |
| 06/15/2011 | EP2333052A1 Desaturase genes and uses thereof |
| 06/15/2011 | EP2332962A1 Cyclopenta[g]quinazoline compounds for use in the treatment of inflammatory or allergic conditions |
| 06/15/2011 | EP2332953A1 Substituted amine derivative and medicinal composition comprising same as the active ingredient |
| 06/15/2011 | EP2332952A1 Modified 2' and 3'-nucleoside prodrugs for treating flaviridae infections |
| 06/15/2011 | EP2332950A1 Epothilone glycoside compounds, compositions containing epothilone glycoside compounds as active components and uses thereof |
| 06/15/2011 | EP2332949A1 Avermectin derivatives |
| 06/15/2011 | EP2332947A1 Solid forms of (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol and methods of their use |
| 06/15/2011 | EP2332943A1 Novel fused aminodihydrothiazine derivative |
| 06/15/2011 | EP2332939A1 Novel Naphthyridine derivatives and the use thereof as kinase inhibitors |
| 06/15/2011 | EP2332938A1 Viral inhibitors |
| 06/15/2011 | EP2332935A1 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |